OCULAR THERAPEUTIX, INC
OCULAR THERAPEUTIX, INC (OCUL): 7 pipeline candidates · 5 upcoming catalysts · ~31 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
30.9 months
D/E 0.26 · 2% dilution
Lead: Approved
7 candidates
5 upcoming, next in ~204d
1 buy · 16 sells (180d)
A transparent, data-derived signal for OCULAR THERAPEUTIX, INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$668.3M
Quarterly Burn
$66.0M
Runway
30.9 mo
Revenue
$10.8M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| AXPAXLI | Phase 3 |
| dextenza | Approved |
| Dextenza 0.4Mg Ophthalmic Insert | Phase 4 |
| Durysta, Bimatoprost Intracameral Implant 10 µg | Phase 2 |
| OTX-TIC | Phase 3 |
| OTX-TKI | Phase 3 |
| resure sealant | Phase 4 |
Upcoming Catalysts (5)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
267
Total value held
$1.50B
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 32,653,764 | $276.6M |
| deep track capital, lp | 19,686,282 | $166.7M |
| vanguard capital management llc | 17,438,078 | $147.7M |
| blackrock, inc. | 16,132,931 | $136.6M |
| alliancebernstein l.p. | 4,129,687 | $50.1M |
| state street corp | 4,708,419 | $39.9M |
| geode capital management, llc | 4,529,185 | $38.4M |
| logos global management lp | 3,850,000 | $32.6M |
| woodline partners lp | 3,335,218 | $28.2M |
| octagon capital advisors lp | 3,166,600 | $26.8M |
Showing top 10 of 267 institutional holders of OCULAR THERAPEUTIX, INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in OCULAR THERAPEUTIX, INC's pipeline?
OCULAR THERAPEUTIX, INC (OCUL) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is OCULAR THERAPEUTIX, INC's lead drug candidate?
OCULAR THERAPEUTIX, INC's most advanced tracked candidate is AXPAXLI (Phase 3) for Wet age-related macular degeneration (wet AMD) and non-proliferative diabetic retinopathy (NPDR).
What is OCULAR THERAPEUTIX, INC's next catalyst?
OCULAR THERAPEUTIX, INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 3, Multicenter, Double-Masked, Randomized, Parallel Group Study to Evaluate the Efficacy and" — expected January 8, 2027.
What is OCULAR THERAPEUTIX, INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, OCULAR THERAPEUTIX, INC has approximately 30.9 months of cash runway.
What is OCULAR THERAPEUTIX, INC's market capitalization?
OCULAR THERAPEUTIX, INC's market capitalization is approximately $2.0B.
Get the full picture on OCULAR THERAPEUTIX, INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.